This heterogeneity will reflect risk groups, prognosis and treatment options and accordingly the international neuroblastoma risk group (INRG) has established a consensus on pre-treatment risk stratification based on differentiation status, histological properties, MYCN status, ploidy, age, segmental chromosomal alterations and stage among other factors [5,6]. The gene discussed is MYCN; the disease is neuroblastoma.